Welcome to our dedicated page for Aptargroup SEC filings (Ticker: ATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AptarGroup, Inc. (ATR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange-listed issuer, Aptar files current reports, annual and quarterly reports and other documents that explain its financial condition, capital structure and material events affecting the business.
Investors can review Form 8-K filings for announcements such as quarterly results and financing transactions. For example, a Form 8-K dated November 20, 2025 describes an underwritten public offering of 4.750% senior notes due 2031, including key terms of the notes, redemption provisions and related underwriting agreements. Other 8-K filings reference the release of quarterly earnings information for periods such as the quarter ended September 30, 2025.
Alongside current reports, users can consult Aptar’s periodic filings, including Form 10-K annual reports and Form 10-Q quarterly reports, which typically provide segment information for Aptar Pharma, Aptar Beauty and Aptar Closures, as well as discussions of risk factors and liquidity. Filings related to debt instruments, indentures and other agreements give additional insight into the company’s capital structure.
Stock Titan enhances these documents with AI-powered tools that summarize key points, highlight significant terms and help explain complex sections in plain language. Users can quickly identify items such as new debt offerings, results of operations disclosures and other material events, while retaining the ability to read the full original filings. This page is a starting point for analyzing how Aptar reports its performance, governance and financing activities to regulators and the market.
AptarGroup, Inc. shareholder has filed a Form 144 notice to sell 2,000 common shares. The planned sale is through UBS Switzerland AG on the NYSE, with an aggregate market value of $272,000 and 66,543,252 shares outstanding. The approximate sale date indicated is February 9, 2026.
The 2,000 common shares were acquired on March 23, 2024 via restricted stock units (RSUs) and performance stock units (PSUs) granted by AptarGroup, Inc., and paid in the form of these equity awards.
AptarGroup, Inc. is a global supplier of dosing, dispensing and protection technologies for pharmaceuticals, beauty, personal care, home care, food and beverage products. The company operates three segments: Pharma, Beauty and Closures.
In 2025, Pharma generated about 46% of net sales and 69% of adjusted EBITDA (excluding non-allocated corporate costs), supplying nasal spray pumps, inhaler valves, injectable elastomer components, active material science solutions and digital health tools. Beauty contributed roughly 35% of net sales with pumps, airless systems and valves for fragrance, skincare, cosmetics and personal care. Closures represented about 19% of net sales, focusing on dispensing closures for food, beverage and personal care applications.
Aptar is geographically diversified, with 57 manufacturing facilities worldwide and approximately 14,000 employees, and no single customer exceeding 4% of 2025 net sales. The company emphasizes sustainability, including science-based emissions targets, recyclable and PCR-based packaging solutions, and multiple external recognitions for environmental and social performance. Recent portfolio moves include acquiring Sommaplast for $27 million, increasing ownership in BTY to 80% for about $29 million, and a 40% stake in Goldrain for about $99 million.
Key risks highlighted include macroeconomic weakness, geopolitical tensions and tariffs, supply chain and single‑source material dependence, cybersecurity threats, foreign currency volatility, labor relations, environmental and packaging regulations, tax changes, climate-related impacts and exposure to routine litigation and regulatory oversight.
AptarGroup reported solid 2025 growth with some margin pressure. Fourth quarter 2025 sales rose 14% to $962.7 million, but net income fell to $74.3 million and diluted EPS declined to $1.13 from $1.49 as mix and higher production costs weighed on profitability.
For full-year 2025, sales increased 5% to $3.78 billion and diluted EPS grew 7% to $5.89, while adjusted EPS slipped 1% to $5.74. Pharma, Beauty and Closures all delivered core sales growth, and adjusted EBITDA margin held at 21.6%. The company generated $570 million in operating cash flow and $302.9 million in free cash flow, ended the year with $410 million in cash and short-term investments and net debt of $1.07 billion, and reported a leverage ratio of 1.38. Aptar returned $486 million to shareholders via dividends and buybacks in 2025, including repurchasing 1.5 million shares for $175 million in the fourth quarter, and its board approved a new authorization to repurchase up to $600 million of common stock. The company guided first quarter 2026 adjusted EPS to $1.13–$1.21 and plans 2026 capital investments of $260–$280 million.
AptarGroup, Inc.'s Chief Accounting Officer reported an insider transaction involving company common stock. On 12/12/2025, the officer exercised stock options for 15,000 shares of AptarGroup common stock at an exercise price of $71.12 per share and received these shares.
On the same date, the officer sold 15,000 shares of AptarGroup common stock at a weighted average price of $121.229 per share, with individual sale prices ranging from $120.8450 to $121.5900.
Following these transactions, the officer directly beneficially owned 29,607 shares of AptarGroup common stock. The stock option covering 15,000 shares, which had been exercisable since 02/05/2017 and was scheduled to expire on 02/05/2026, was fully exercised, leaving no remaining derivative securities from that grant.
A holder of Common stock of the issuer with symbol ATR filed a notice to sell 15,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The shares have an indicated aggregate market value of $1,818,435.00, compared with 65,619,154 shares of the same class reported as outstanding. The seller acquired these 15,000 shares on 12/12/2025 by exercising options under a registered plan and paid the purchase price in cash on the same date.
AptarGroup, Inc. completed an underwritten public offering of $600 million aggregate principal amount of its 4.750% Senior Notes due 2031. The notes mature on March 30, 2031 and carry a fixed interest rate of 4.750% per year, paid semi-annually on March 30 and September 30, starting March 30, 2026. These notes are unsecured and rank equally with the company’s other senior unsecured debt.
The company can redeem the notes before February 28, 2031 at a make-whole price, and on or after that date at 100% of principal plus accrued interest. If a defined change of control repurchase event occurs and the notes are not redeemed, holders can require AptarGroup to repurchase their notes at 101% of principal plus accrued interest. The indenture includes typical covenants limiting certain liens, sale-leaseback transactions, and major corporate reorganizations, along with standard events of default and acceleration provisions.
AptarGroup, Inc. is issuing $600,000,000 of 4.750% Senior Notes due March 30, 2031. The notes pay interest semi-annually starting March 30, 2026 and are unsecured, unsubordinated obligations ranking equally with Aptar’s other unsecured senior debt and structurally behind liabilities at its subsidiaries. The public offering price is 99.917%, providing estimated net proceeds of about $593.9 million after fees. Aptar plans to use the proceeds to repay all $125.0 million of its 3.61% senior unsecured notes due 2025, all $125.0 million of its 3.61% senior unsecured notes due 2026, and all outstanding U.S. dollar borrowings under its revolving credit facility, with any remainder for general corporate purposes. The notes are callable at a make-whole price before February 28, 2031 and at par thereafter, and investors receive a 101% repurchase right if a defined change of control and ratings downgrade occur.
AptarGroup, Inc. plans to issue new unsecured senior notes to refinance existing borrowings. The notes rank equally with Aptar’s other unsecured debt, are structurally junior to subsidiary liabilities, and include optional redemption and a 101% repurchase feature if a change of control and ratings downgrade occur. Net proceeds are expected to repay all $125.0 million 3.61% notes due 2025, all $125.0 million 3.61% notes due 2026, and outstanding U.S. dollar borrowings under the revolving credit facility, with any remainder for general corporate purposes. Aptar reports net sales of $2,814.4 million and net income attributable to Aptar of $318.4 million for the nine months ended September 30, 2025, with Net Debt of $935.6 million and Net Debt to Net Capital of 25.1% as of that date.
AptarGroup (ATR) reported an initial Form 3 for Irene Hudson, EVP and Chief Legal Officer. She directly owns 798 shares of common stock and holds stock options for 842 shares at $111.38 expiring 03/15/2033, 1,189 shares at $141 expiring 03/15/2034, and 1,030 shares at $147.84 expiring 03/17/2035. Each option vests in three equal installments beginning on the first anniversary of the grant date.
AptarGroup (ATR) reported higher Q3 2025 revenue and earnings. Net sales rose to $961.1 million from $909.3 million, led by Aptar Pharma ($445.4 million), Beauty ($327.8 million) and Closures ($188.0 million). Operating income was $136.9 million versus $138.3 million a year ago. Other income benefited from a $26.5 million gain from remeasurement of an equity method investment.
Profitability improved year over year. Net income attributable to AptarGroup was $127.9 million (diluted EPS $1.92) versus $100.0 million ($1.48). For nine months, sales reached $2.81 billion with net income of $318.4 million (EPS $4.75) versus $2.73 billion and $273.6 million (EPS $4.05).
Balance sheet and cash flow remained solid. Cash and equivalents were $257.1 million; total assets were $5.10 billion. Net cash provided by operations was $386.3 million. The company used cash for capital expenditures ($183.6 million), treasury stock purchases ($190.0 million) and dividends ($89.3 million). Revolving credit borrowings totaled $187.0 million and €130.0 million under the amended facility. Leverage and coverage remained well within covenants at 1.22x and 17.02x, respectively. Shares outstanding were 65,619,154 as of October 27, 2025.